Patient characteristics at diagnosis plus frequency and type of hematologic toxicity during treatment
| Diagnostic features . | No MDS-PA (n = 1182; 94.4%) . | MDS-PA (n = 70; 5.6%) . | P . |
|---|---|---|---|
| Age, y* | 60 | 65 | .04 |
| Male sex | 659 (53%) | 38 (54%) | .86 |
| Hemoglobin, g/dL* | 106 | 97 | <.001 |
| LDH (elevated) | 154 (13%) | 15 (21.4%) | .04 |
| ISS stage (n = 1211) | n = 1143 | n = 68 | |
| I | 405 (35.4%) | 14 (20.6%) | .007 |
| II | 462 (40.4%) | 27 (39.7%) | .507 |
| III | 276 (24.2%) | 27 (39.7%) | .004 |
| Isotype (n = 1239) | n = 1171 | n = 68 | |
| IgG | 689 (58.8%) | 32 (47%) | .038 |
| IgA | 291 (24.9%) | 19 (27.9%) | .328 |
| IgD | 9 (0.77%) | 1 (2.1%) | .433 |
| IgM | 1 (0.09%) | — | — |
| Light chain | 181 (15.5%) | 16 (23%) | .060 |
| Plasma cells, %* | 35 | 54 | .002 |
| Cytogenetics (n = 772) | n = 726 | n = 46 | |
| Standard-risk | 581 (80%) | 37 (80%) | .562 |
| High-risk† | 145 (20%) | 9 (20%) | .562 |
| Diagnostic features . | No MDS-PA (n = 1182; 94.4%) . | MDS-PA (n = 70; 5.6%) . | P . |
|---|---|---|---|
| Age, y* | 60 | 65 | .04 |
| Male sex | 659 (53%) | 38 (54%) | .86 |
| Hemoglobin, g/dL* | 106 | 97 | <.001 |
| LDH (elevated) | 154 (13%) | 15 (21.4%) | .04 |
| ISS stage (n = 1211) | n = 1143 | n = 68 | |
| I | 405 (35.4%) | 14 (20.6%) | .007 |
| II | 462 (40.4%) | 27 (39.7%) | .507 |
| III | 276 (24.2%) | 27 (39.7%) | .004 |
| Isotype (n = 1239) | n = 1171 | n = 68 | |
| IgG | 689 (58.8%) | 32 (47%) | .038 |
| IgA | 291 (24.9%) | 19 (27.9%) | .328 |
| IgD | 9 (0.77%) | 1 (2.1%) | .433 |
| IgM | 1 (0.09%) | — | — |
| Light chain | 181 (15.5%) | 16 (23%) | .060 |
| Plasma cells, %* | 35 | 54 | .002 |
| Cytogenetics (n = 772) | n = 726 | n = 46 | |
| Standard-risk | 581 (80%) | 37 (80%) | .562 |
| High-risk† | 145 (20%) | 9 (20%) | .562 |
| Hematologic toxicity‡ . | No MDS-PA (n = 736; 94.8%) . | MDS-PA (n = 40; 5.3%) . | P . |
|---|---|---|---|
| Anemia | 405 (55%) | 32 (80%) | .002 |
| Neutropenia | 364 (50%) | 28 (70%) | .011 |
| Thrombocytopenia | 195 (27%) | 11 (28%) | .889 |
| Hematologic toxicity‡ . | No MDS-PA (n = 736; 94.8%) . | MDS-PA (n = 40; 5.3%) . | P . |
|---|---|---|---|
| Anemia | 405 (55%) | 32 (80%) | .002 |
| Neutropenia | 364 (50%) | 28 (70%) | .011 |
| Thrombocytopenia | 195 (27%) | 11 (28%) | .889 |